scholarly journals Cecal Perforation in a COVID-19 Patient Treated with Tocilizumab: A Case Report

2021 ◽  
pp. 1-3
Author(s):  
Victor Dominguez Prieto ◽  
Victor Dominguez Prieto ◽  
Cecilia Meliga ◽  
Sara Rosenstone ◽  
Siyuan Qian Zhang ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Immune Response ◽  
Case Report ◽  
Treatment Option ◽  
Interleukin 6 ◽  
Antiviral Drugs ◽  
Gastrointestinal Perforation ◽  
Lung Damage ◽  
Cecal Perforation ◽  
Interleukin 6 Receptor

Tocilizumab is a monoclonal antibody against the interleukin-6 receptor. Gastrointestinal perforation has been associated with Tocilizumab treatment. In the absence of specific antiviral drugs, Tocilizumab is currently being used as a treatment option in patients with severe COVID-19 pneumonia. This is being based on the implication of interleukin-6 in the aberrant host immune response that characterizes the disease and initiates patients' lung damage. Herein we present the case of a cecal perforation in a patient treated with Tocilizumab for COVID-19. In such context, we expect that there may be an increase in the incidence of gastrointestinal perforation related to Tocilizumab.

Successful Treatment of Refractory Takayasu Arteritis with Tocilizumab—A Case Report

2018 ◽  
Vol 1 (2) ◽  
pp. 133-135
Author(s):  
Nambiar Vivek K. ◽  
T.S. Dhanya ◽  
Ajai Amrutha V.
Keyword(s):  
Monoclonal Antibody ◽  
Case Report ◽  
Successful Treatment ◽  
Takayasu Arteritis ◽  
Interleukin 6 ◽  
Biological Agents ◽  
Young Females ◽  
Duration Of Therapy ◽  
Humanized Monoclonal Antibody ◽  
Interleukin 6 Receptor

Takayasu arteritis (TA) is an idiopathic inflammatory vasculitis mostly affecting young females in the second or third decades of life. Corticosteroids and conventional immunosuppressants remain the mainstay of treatment for TA, but refractory cases are dealt with biological agents. The high cost and longer duration of therapy are issues of concern. Here, we report a case of a patient with refractory TA who underwent successful treatment with tocilizumab, a humanized monoclonal antibody against interleukin-6 receptor.

scholarly journals Soluble Interleukin-6 Receptor-Mediated Innate Immune Response to DNA and RNA Viruses

2013 ◽  
Vol 87 (20) ◽  
pp. 11244-11254 ◽  
Author(s):  
Q. Wang ◽  
X. Chen ◽  
J. Feng ◽  
Y. Cao ◽  
Y. Song ◽  
...  
Keyword(s):  
Immune Response ◽  
Innate Immune Response ◽  
Interleukin 6 ◽  
Rna Viruses ◽  
Innate Immune ◽  
Dna And Rna ◽  
Interleukin 6 Receptor

Tocilizumab: From Rheumatic Diseases to Covid-19

2021 ◽  
Vol 27 ◽  
Author(s):  
Alberto Raiteri ◽  
Fabio Piscaglia ◽  
Alessandro Granito ◽  
Francesco Tovoli
Keyword(s):  
Rheumatoid Arthritis ◽  
Monoclonal Antibody ◽  
Interleukin 6 ◽  
Organ Damage ◽  
Efficacy And Safety ◽  
Antiviral Effects ◽  
Number Of Patients ◽  
Interleukin 6 Receptor ◽  
Overall Evaluation ◽  
Scientific Rationale

: Tocilizumab is a humanised interleukin-6 receptor-inhibiting monoclonal antibody that is currently approved for the treatment of rheumatoid arthritis and other immune-related conditions. Recently, tocilizumab has been investigated as a possible treatment for severe coronavirus-induced disease 2019 (COVID-19). Despite the lack of direct antiviral effects, tocilizumab could reduce the immune-induced organ damage caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infection. Until recently, most reports on tocilizumab for COVID-19 included a limited number of patients, preventing an overall evaluation of its efficacy and safety for this specific condition. Therefore, we reviewed the literature regarding the physiopathological rationale of tocilizumab for COVID-19 and its outcomes. We searched the MEDLINE database with the string “(SARS-CoV-2 OR coronavirus OR COVID-19 OR MERS-cov OR SARS-cov) AND (IL-6 OR interleukin 6 OR tocilizumab)”. While the scientific rationale supporting tocilizumab for COVID-19 is solid, the evidence regarding the outcomes remains controversial. Available data and results from ongoing trials will provide useful information in the event of new COVID-19 outbreaks or future pandemics from different coronaviruses.

Effects of SA237, a humanized anti-interleukin-6 receptor monoclonal antibody, on pre- and postnatal development in cynomolgus monkey

2017 ◽  
Vol 109 (11) ◽  
pp. 843-856 ◽  
Author(s):  
Ryuichi Katagiri ◽  
Kana Ishihara-Hattori ◽  
Werner Frings ◽  
Jun Amano ◽  
Antje Fuchs ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Postnatal Development ◽  
Interleukin 6 ◽  
Cynomolgus Monkey ◽  
Interleukin 6 Receptor ◽  
Receptor Monoclonal Antibody
Sign in / Sign up

Export Citation Format

Share Document